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1. INTRODUCTION: 
 
The introduction of Gall Bladder disease to mankind dates back to the 21st 
Egyptian dynasty (1085-945BC), when gall stones were discovered in the 
mummy of priestess of Amen. Williams et al (1989) described Gall Bladder as 
slate blue, pyriform sac sunken in fossa in the right hepatic lobes inferior 
surface. 
Cholelithiais is a disease prevalent worldwide because of an imbalance of bile 
salt and cholesterol concentrations that leads to precipitation inside the 
gallbladder. Gall stones is the most common biliary pathology both in India and 
western countries. In western countries 10-12% of adults [1-2] develop 
gallstones. A gallstones survey suggested that gallbladder stones occurred 7 
times more commonly in north Indians than in south Indians. The prevalence of 
common bile duct stones in patients with gallstones varies from 8 to16% [4]. 
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Cholesterol stones-Pure cholesterol stones are not very common. It accounts for 
less than 10% of all stones. It usually present as a single large stones with 
smooth surface. Most of the other cholesterol stones contain variable amount of 
bile pigments and calcium. They are always more than 70% cholesterol by 
weight. These stones are usually multiple in number with variable sizes, and 
may be hard and faceted or irregular, mulberry shape and soft. Color ranges 
from whitish yellow and green to black. Most cholesterol stones are radiolucent. 
Among that radiopaque are less than 10%. Super saturation of bile with 
cholesterol is the common primary event in the formation of cholesterol stone. 
Similar in both kind of stones, pure or of mix nature. Super saturation almost 
always is due to cholesterol hyper secretion but not caused by reduced secretion 
of phospholipids or bile salts. 
Pigment stones contain less than 20% cholesterol and are dark because of 
presence of calcium bilirubinate. Black pigment stones are characterized as 
small, brittle, black and sometimes speculated. They are formed by super 
saturation of calcium bilirubinate, carbonate and phosphate. They are formed 
most often secondary to hemolytic disorder such as hereditary spherocytosis 
and sickle cell anemia. Like cholesterol stones they are almost always found in 
gall bladder. 
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Bile stasis, bactibilia, chemical imbalances, pH imbalances, change of bile 
composition and formation of sludge are among the principle factors thought to 
lead to formation of gallstones. Thyroid diseases are, arguably, among the 
commonest endocrine disorders worldwide. India too is no exception. 
For decades there has been discussion whether thyroid disorders could cause 
gall stone disease. There could be several explanations for possible relation 
between hypothyroidism and gall stone disease. Previously described that 
thyroid hormones are having a number of effects on cholesterol metabolism [5]. 
In hypothyroidism serum cholesterol values rises which in turn leads to super 
saturation of bile with cholesterol, leading to gallbladder hypo motility, 
decreased contractibility and impaired filling, giving rise to [6-8] prolonged 
residence and flow capacity of bile in the gallbladder. These events may 
contribute to the retention of cholesterol crystals, thereby allowing sufficient 
time for nucleation and continual growth into mature [6] gall stones. In 
addition, the rate of bile secretion may be [9] decreased, physically impairing 
clearance of precipitates from the bile ducts and gallbladder. Furthermore, the 
sphincter of oddi described to have a thyroid hormone receptors. Thyroxin has a 
direct pro relaxing effect on the sphincter. Both low bile flow and sphincter of 
oddi dysfunction are regarded as important functional mechanism that [10] may 
promote gall stone formation.  A crucial factor in forming of bile duct stones is 
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biliary stasis, which may be caused by sphincter of oddi stenosis, dyskinesia, or 
bile duct strictures. 
Recent studies concentrate on gall stones and thyroid hormones – T3 and T4 
have effect on both bile content and bile flow. Patients with hypothyroidism 
have serum level of cholesterol approximately 50% higher level than in 
euthyroid patients and 90% of all hypothyroid patients have elevated 
cholesterol level. Likewise low levels of t4 have an effect in relaxing the 
sphincter of oddi, leading to biliary stasis and stone formation [11]. 
Only in 50% of cases, ultrasonography actually visualizes bile duct stones. 
About 75% of cases of bile duct with a diameter greater than 6mm is seen in 
ultrasonography. Endoscopic retrograde cholangiopancreatography (ERCP) is 
the standard method for the diagnosis and therapy of bile duct stones. Having 
sensitivity and specificity rates of approximately 95%. 
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2. AIM AND OBJECTIVE OF THE STUDY: 
 
1. To know the prevalence of hypothyroidism in diagnosed cases of gall stone 
disease. 
2. To check thyroid hormone levels TSH, free T3 and free T4 in patients who 
are diagnosed with gallstone diseases.  
3. To check thyroid status in patients who are diagnosed with gallstone disease, 
there by dividing into euthyroid, hypothyroid, hyperthyroid and sub clinically 
hypothyroid, correlating the prevalence of subclinical hypothyroidism in 
patients with cholelithiasis. 
4. To investigate the prevalence of undiagnosed thyroid dysfunction in CBD 
stone patients. 
5. To check lipid parameters in patient with gall bladder diseases in relation to 
TSH. 
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6. Comparison of lipid parameters in gall stone patients with and without 
thyroid dysfunction. 
 
 
 
3. REVIEW OF LITERATURE: 
 
3.1 HISTORY:  
Gallstones and CBD stones have been described long before the era of modern 
abdominal surgery. Numerous calculi were found in the mummy of a priestess of 
Amenen of the 21st Egyptian dynasty 1500BC. Vesalius and fallopius in 16th 
century described gall stones in human bodies. 
The first cholescystostomy was performed in 1867 by John stough hobbs and first 
cholecystectomy was performed by Carl laugenbuch in 1882 in Berlin. 
The CBD exploration was carried out of Kurnmel in 1884 and first performed 
successfully by Thornton in 1887. 
1891 – Oskar sprengel – choledochoduodenostomy 
1890 – Harskeer – T-tube 
1921 – Busckhardt and Mueller – Trans hepatic gall bladder puncture 
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1923 – Cole – cholecystography 
1924 – Cotte – post surgical cholangiography 
1974 – Kawaiet al – endoscopic sphincterotomy 
1987 – Hourt – laparoscopic cholecystectomy 
 
3.2 SURGICAL ANATOMY: 
3.2.1 EXTRAHEPATIC BILIARY TRACT 
Extra hepatic biliary tract consists of bifurcation of right and left hepatic duct, 
common hepatic duct, gallbladder, cystic duct and CBD. 
Right and left lobes are drained by ducts originating as bile canaliculi in the 
lobules and the canaliculi empty into canals of herring in interlobular triads, these 
canals are collected into ducts and finally outside the liver, the right and left 
hepatic duct. 
Left hepatic duct is formed by the ducts draining segments II, III, IV of liver and 
has longer extra hepatic length of > 2cm with greater propensity for dilatation as a 
consequence of distal obstruction. 
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Right hepatic duct is formed by the right posterior (segments VI, VII) and right 
anterior (segments V, VIII) hepatic ducts and has a short extra hepatic length of 0.9 
cm. Hepatic duct bifurcation is usually extra hepatic and anterior to portal vein 
bifurcation, with a length of 1-4 cms and diameter of 4mm common hepatic duct 
lies anteriorly in the hepato duodenal ligament and joins the cystic duct to form 
CBD. 
3.2.2 CYSTIC DUCT: 
Arise from gall bladder, joins common hepatic duct at an angle of about 40 degree. 
Length of cystic duct and manner in which it joints hepatic duct varies and is of 
surgical importance. 
Cystic duct contains variable number of mucosal folds, the valves of Heiester 
without valvular function. 
 
3.2.3 GALLBLADDER ANATOMY:  
The gallbladder stores and concentrates the bile secreted by the liver. The 
transverse septum modified to form the hepatic diverticulum and the hepatic 
primordium. These two structures together will become different components of 
the mature liver and gall bladder in future. 
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The hepatic diverticulum cleaves into two parts. Namely, pars hepatica (larger 
cranial part, primordium of the liver) and pars cystica (smaller ventral 
invagination, primordium of gall bladder). 
The pars cystica expands into the stalk, which in turn will be becoming the cystic 
duct. This structure is initially hollow, which then becomes solid due to 
proliferation of epithelial lining. Later it recanalized occurs by vacuolation of this 
expanded epithelium. This is for open discussion whether the duct has a solid 
phase or remains patent throughout development. 
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It is a globular or pear-shaped viscous with a capacity of about 50 mL. It is 7 to 10 
cm long and 3 to 4 cm broad at its widest part. It is divided into three parts namely; 
fundus, body and neck. It lies over the gallbladder fossa of visceral surface in the 
right lobe of the liver, adjacent to the quadrate lobe. 
The fundus part of the gallbladder usually protrude or extends about 1cm beyond 
the free edge lower border of the liver. That protruded part touches the parietal 
peritoneum of the anterior abdominal wall at the tip of the ninth costal cartilage, at 
the lateral border of the right rectus sheath. At this point the trans pyloric plane 
crosses the right costal margin. This is the surface marking for the fundus and the 
area of abdominal tenderness in gallbladder disease. (The fundus of the normal 
gallbladder is not palpable but may become so if distended by biliary tract 
obstruction.) The fundus rest on the commencement of the transverse colon, near 
the left of the hepatic flexure. The body extends up to the right end of the portal 
hepatis and touches the D1 part of the duodenum. The upper limit of the body 
narrows into the neck. The neck is the tapered segment of the infundibulum that is 
narrow and joins the cystic duct. The cystic duct is 2 to 3 cm long and 2 to 3 mm in 
diameter. It passes backwards, downwards and to the left to join the common 
hepatic duct, mainly in front of the right hepatic artery and its cystic branch (but 
variations are common). The infundibulum is the transitional area between the 
body and the neck. Hartmann’s pouch is a bulge on the inferior surface of the 
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infundibulum. This is not a feature of the normal gallbladder and is always 
associated with a pathological condition; it may be the site of impaction of a 
gallstone. 
Small cystic veins and bile ducts pass mainly from the fundus and body of the 
gallbladder into the liver substance. If these are undetected they may drain bile into 
the peritoneal cavity after cholecystectomy. The peritoneum covering the liver 
moves smoothly over the gallbladder. Sometimes the gallbladder suspends free 
from a narrow ‘mesentery’ from the under surface of the liver. Rarely the 
gallbladder may be embedded within the liver. Very rarely the gallbladder may be 
absent. 
The gallbladder varies in size and shape. In rare cases it is duplicated with single or 
double cystic ducts. It may be septate with the lumen divided into two chambers. 
The fundus may be folded in the manner of a Phrygian cap; this is the most 
common congenital abnormality. 
Calot triangle 1st described by Calot in 1891. Calot triangle formed by formed by 
the cystic artery superiorly, the common hepatic duct medially, and the cystic duct 
laterally. Many believe that upper boundary of Calot triangle is formed by the 
inferior surface of the liver, rather than the cystic artery. A thorough knowledge of 
the anatomy of Calot triangle is very important during cholecystectomy as many 
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structure passes through it. In several instances, within this triangle the right 
hepatic artery may give branch to the cystic artery. In few times, right hepatic 
artery arising from the superior mesenteric artery may passes through medial part 
of the triangle behind cystic. 
Sometimes structures like accessory hepatic duct before joining the cystic duct or 
CBD may travel through calot triangle. During performance of a cholecystectomy, 
clear visualization of the hepatocystic triangle is essential with accurate 
identification of all structures within this triangle. 
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Blood supply: 
Main blood supply to gallbladder is the cystic artery. Cystic artery arises from the 
right hepatic artery. The cystic artery forms the superior border of the calot 
triangle. Variations in the origin of the cystic artery are common. Like, arising of 
the cystic artery from the main trunk of the hepatic artery, from the left branch of 
the hepatic artery or from gastroduodenal artery. In all these cases artery pass in 
front of the cystic and bile duct. 
Venous return is mainly from multiple small veins of the gallbladder to the 
substance of the liver which in turn will lead to hepatic veins. In uncommon 
presentations, cystic artery runs from the neck of the gallbladder to the right branch 
of the portal vein. Cystic veins do not coexist with the cystic artery. 
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Lymph drainage: 
Lymphatic drainage of the gallbladder will drain into nodes in the porta hepatis, 
cystic node situated in the calots’s triangle and to a node at the anterior boundary 
of the epiploic foramen. Finally it will drain into the coeliac group of pre aortic 
nodes. 
 
 
3.2.4 SPHINCTER OF ODDI: 
The complete sphincteric system of the distal bile duct and the pancreatic duct is 
usually referred to as the sphincter of oddi. This term is imprecise because the 
sphincter is subdivided into several sections and contains both circular and 
longitudinal fibers. The sphincter mechanism functions independently from the 
surrounding duodenal musculature. The sphincters for the distal bile duct, the 
pancreatic duct, and the ampulla are individually separated. In most of the 
population, the biliary and pancreatic ducts joins into common channel with in 
ampulla which of length less than 1 cm. In very rare cases, it will be more than 1 
cm in length or both of them will open separately into the duodenum. In these rare 
presentation may leads to pathologic biliary or pancreatic problems. The Entire 
sphincter mechanism is actually composed of four sphincters containing both 
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circular and longitudinal smooth muscle fibers. The four sphincters are the superior 
and inferior sphincter choledochus, the sphincter pancreaticus, and the sphincter of 
the ampulla.  
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3.2.5 BILE DUCT: 
The bile duct (formerly called the common bile duct) is about 6 to 8 cm long and 
its normal diameter does not exceed 8 mm. It is best described in three parts or 
thirds. The upper (supraduodenal) third lies in the free edge of the lesser omentum 
in the most accessible position for surgery-in front of the portal vein and to the 
right of the hepatic artery, where the lesser omentum forms the anterior boundary 
of the epiploic foramen. The middle (retro duodenal) third runs behind the first part 
of the duodenum and slopes down to the right, away from the almost vertical portal 
vein which now lies to the left of the duct with the gastro duodenal artery. The 
inferior vena cava is behind the duct. The lower (paraduodenal) third slopes further 
to the right in a groove on the back of the head of the pancreas (it may even be 
embedded in a tunnel of pancreatic tissue) and in front of the right renal vein. 
Neoplasms of the head of the pancreas may obstruct the duct here. It joins the 
pancreatic duct at an angle of about 60° at the hepatopancreatic ampulla (of Vater). 
The ampulla and the ends of the two ducts are each surrounded by sphincteric 
muscle, the whole constituting the ampullary sphincter (of Oddi). Sometimes the 
muscle fibers surrounding the ampulla and the pancreatic duct are absent, leaving 
only the bile duct sphincter. When all three are present the arrangement allows for 
25 
 
independent control of flow from bile and pancreatic ducts. The ampulla itself 
opens into the posteromedial wall of the second part of the duodenum at the major 
duodenal papilla, which is situated 10 cm from the pylorus. 
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3.3 PHYSIOLOGY:  
3.3.4 BILE FORMATION: 
The formation of bile by the hepatocyte serves two purposes. Bile is regarded as 
the route of excretion for certain organic solutes, such as bilirubin and cholesterol. 
It helps to absorb lipids and fat-soluble vitamins in intestine. Bile is formed in tiny 
vacuoles in hepatocytes and is discharged into bile canaliculus. By active transport 
of salutes and passive flow of water.  Approximately 85% of the volume of bile is 
composite of water. Bilirubin, bile salts, phospholipids, and cholesterol are 
considered as the major organic solutes in bile. Spent red blood cells breakdown to 
form bilirubin. It is conjugated with glucuronic acid with the help of the hepatic 
enzyme glucuronyltransferase. Conjugated bilirubin is excreted actively into the 
adjacent canaliculus. The primary bile salts are steroid molecules synthesized from 
cholesterol by the hepatocyte. 
The Primary bile salts in humans mainly constitutes of cholic and 
chenodeoxycholic acid. They reach duodenum through bile and in the small 
intestine and colon they are converted into secondary bile acids- deoxycholic acid 
and lithocholic acid by bacterial action. The important function of bile salts is to 
hide in the absorption of lipids by increasing its solubility. Phospholipids are 
synthesized in the liver when bile salt are synthesized. Lecithin is the primary 
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phospholipid in human bile. Lecithin constitute more than 95% of the total 
phospholipids. Cholesterol is the final major solute of bile. Liver is the primary 
source for cholesterol with little from dietary source. 
The volume of bile secretion daily in normal circumstances is around 750 to 100 
mL. Bile secretion controlled by three mechanisms; neurogenic, hormonal, and 
chemical control. Bile secretion is increased by stimulating vagal stimulations and 
bile secretion is decreased by splanchnic stimulation (decreases hepatic blood flow 
by vasoconstriction). Gastrointestinal hormones increases bile flow by increasing 
water and electrolyte secretion. Hormones are secretin, cholecystokinin, gastrin, 
and glucagon. Finally, the rate at which bile salts synthesized by hepatocyte is the 
most important factor for regulation of the volume of bile flow. The enterohepatic 
circulation regulates this step by regulating the return of bile salts to the liver. 
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3.3.5 ENTEROHEPATIC CIRCULATION:   
Bile salts as described above are mainly synthesized and conjugated in the liver 
and secreted into bile. Gallbladder acts as a temporary storage for bile and later 
secreted into duodenum. These bile gets absorbed all over the small intestine but 
mainly in the ileum. After getting absorbed in the ileum it will return back to liver 
via portal vein. This cycle of bile acids circulation between the liver and the 
intestine is called as the enterohepatic circulation. Almost 95% of bile salts get 
reabsorbed during this circulation and it is very effective. Thus, approximately 600 
mg of bile is excreted into the colon, of the total of 2 to 4g bile salt pool. It will 
recycles about 6 to 10 times per day by the enterohepatic circulation. The primary 
bile salts like cholate and chenodeoxycholate is converted into secondary bile salts 
deoxycholate and lithocholate by bacterial action in the colon. Deoxycholate is 
mainly excreted as fecal waste but some of them reabsorbed in the colon. 
The enter hepatic circulation acts like a negative feedback system on the synthesis 
of bile salts. Some of the pathological conditions like resection of the terminal 
ileum, primary ileal disease and external biliary fistula affects enterohepatic 
circulation. In these cases there will be increase in the synthesis of bile salts as 
there will be excess loss of bile. These will takes by proper maintaining a constant 
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bile pool. During fasting most of the bile pool (90%) sequestered in the 
gallbladder. 
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3.4 THYROID ANATOMY AND PHYSIOLOGY: 
A butterfly-shaped organ, the thyroid gland is located anterior to the trachea, just 
inferior to the larynx. The thyroid gland is situated low down at the front of the 
neck. It consists of two symmetrical lobes united by an isthmus that lies in front of 
the second, third and fourth tracheal rings. The lobes lie on either side of the larynx 
and trachea, extending from the oblique line of the thyroid cartilage to the sixth 
tracheal ring. It weighs about 25 g. In addition to its own capsule, the gland is 
enclosed by an envelope of pretracheal fascia. 
Each lateral lobe is pear-shaped with a narrow upper pole and a broader lower 
pole, and appears approximately triangular on cross-section with lateral, medial 
and posterior surfaces. The lateral (superficial) surface is under cover of 
sternothyroid and sternohyoid. The medial surface lies against the lateral side of 
the larynx and upper trachea, with the lower pharynx and upper esophagus 
immediately behind. This surface is related to the cricothyroid muscle of the larynx 
and the inferior constrictor of the pharynx, as well as to the external and recurrent 
laryngeal nerves. The posterior surface overlaps the medial part of the carotid 
sheath, i.e. the part containing the common carotid artery; if enlarged, the lobe may 
extend across the more laterally placed internal jugular vein. The parathyroid 
glands usually lie in contact with this surface, between it and the fascial sheath. 
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3.4.1 STRUCTURE: 
The thyroid consists essentially of a mass of more or less rounded follicles 
containing varying amounts of colloid produced by the single layer of epithelial 
(follicular) cells that form the walls of the follicles. The thyroid is unique in being 
the only endocrine gland to store its secretion outside the cells. The colloid is 
iodinated when in the follicle and reabsorbed by the cells before being discharged 
into blood capillaries. The main hormonal products are thyroxine (T4) and 
triiodothyronine (T3). Less than 2% of the epithelial cells are the C or 
parafollicular cells which secrete calcitonin. The C cells are scattered on the outer 
aspects of the follicles and do not reach the lumina of the follicles. The thyroid 
gland is highly vascular. 
Development: 
The gland develops as a proliferation of cells from the caudal end of the 
thyroglossal duct. The parafollicular calcitonin-producing cells develop from the 
ultimobranchial body (fifth pharyngepouch), under the influence of neural crest 
cells.  
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Blood supply:  
Superior thyroid artery is a branch of external carotid artery. Runs downloads and 
forwards with intimate relation to the external laryngeal nerve. Divides into 
anterior and posterior branches. Inferior thyroid artery is a branch of the 
thyrocervical trunk from the subclavian artery. Runs first upwards, then medially 
and finally downloads to reach the lower pole of the thyroid lobe. Its terminal part 
is intimately related to the recurrent laryngeal nerve. Thyroid ima artery arises 
from the brachiocephalic artery or the aortic arch ascends in front of the trachea to 
reach the isthmus. Accessory thyroid arteries come from the tracheal and 
esophageal vessels. 
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Venous drainage: 
Superior thyroid veins, emerges from the apex of each lateral lobe, draining in the 
internal jugular vein. Middle thyroid veins, emerges from the lower part of each 
lateral lobe. Inferior thyroid veins, emerges from the isthmus and lower part of the 
lateral lobe. Draining via plexus thyreoidea impar in the left brachiocephalic vein. 
 
 
 
 
36 
 
 
3.4.2 SYNTHESIS AND RELEASE OF THYROID HORMONE: 
3.4.2.1 Steps involved in Thyroid Hormone Synthesis: 
Iodide Trapping 
Formation & Secretion of Thyroglobulin 
Oxidation of Iodide 
Organification & Coupling 
Storage of Thyroid Hormones 
Deiodination of Iodothronines 
Release of Thyroid Hormones 
Peripheral conversion of T4 to T3 
Iodine-Essential for Thyroid Hormone Synthesis: 
Iodine is an essential raw material for thyroid hormone synthesis. The minimum 
daily iodine intake that will maintain normal thyroid function is 150 g in adults. 
Average dietary intake is approximately 500 g/d. About 120 g/d enter the thyroid. 
The thyroid secretes 80 g/d in the form of T3 and T4. 40 g/d diffuses back into the 
extracellular fluid (ECF). Circulating T3 and T4 are metabolized in the liver. The 
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total amount of I– entering the ECF is 600 g/d; 20% of this I– enters the thyroid, 
whereas 80% is excreted in the urine. 
Iodide Trapping: 
The first step in Thyroid Hormone Synthesis. The Basolateral membrane of 
Thyrocytes possesses a pump called Na+/I- Symporter. Na+/I symporter transports 
two Na+ ions and one I- ion into the cell with each cycle, against the 
electrochemical gradient for I-. Concentration of TSH is the strongest regulator of 
Iodide Trapping Symport mechanism  
Thyroglobulin: 
Thyroglobulin is synthesized by the thyroctes Thyroglobulin, is a glycoprotein 
molecule with a molecular weight of about 335,000. Each molecule of 
thyroglobulin is made up of 2 subunits. Each molecule contains about 70 tyrosine 
residues 
Oxidation of Iodide: 
Once iodide is inside the Thyroid cells, it is converted into an oxidized form of 
iodine, either nascent iodine (I0) or I3.Oxidized Iodine is capable of combining 
directly with the amino acid tyrosine. This oxidation of iodine is promoted by the 
enzyme peroxidase 
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Organification of Thyroglobulin: 
The binding of iodine with the thyroglobulin molecule is called organification of 
the thyroglobulin. Thyroid peroxidase catalyzes the iodination of tyrosine residues. 
Tyrosine is first iodized to monoiodotyrosine and then to diiodotyrosine. 
 
Coupling Reaction: 
Iodotyrosine residues become coupled with one another. Thyroid peroxidase is 
involved in coupling Reaction. T4 is formed by condensation of two molecules of 
DIT. T3 is formed by condensation of MIT with DIT. A small amount of Reverse 
T3, RT3 is also formed, probably by condensation of DIT with MIT. The major 
hormonal product of the coupling reaction is the molecule thyroxine that remains 
part of the thyroglobulin molecule. Triiodothyronine represents about one fifteenth 
of the final hormones. 
Storage of Thyroid Hormones: 
The thyroid gland is unusual among the endocrine glands in its ability to store 
large amounts of hormone. Each thyroglobulin molecule contains up to 30 
thyroxine molecules and a few triiodothyronine molecules. Stored Thyroid 
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Hormones maintain the body’s requirement of T3 and T4 for up to 2-3 months. 
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3.4.2.2 Release of Thyroid Hormones: 
Thyroglobulin itself is not secreted into the circulation. Thyroglobulin is digested 
by pinocytosis mechanism at the apical membrane. T3 and T4 are released, diffuse 
into the capillaries through the basal surface. 
Deiodination of Iodothronines: 
During digestion of thyroglobulin, iodothyronins are also freed but not released in 
to the blood. Enzyme Deiodinase cleaves Iodine from them making it available for 
more and more thyroid hormone synthesis inside the gland. 
Thyroid Hormone Secretion: 
About 93 per cent of the thyroid hormone released from the thyroid gland is 
normally thyroxine, only 7 per cent is triiodothyronine. At the target tissue, most of 
T4 is converted to T3 as T3 is the active form that binds with receptors.  
Thyroid Hormone Transport & Protein Binding: 
Once into the circulation, T3 and T4 bind to plasma proteins synthesized by the 
liver. 
These proteins include: 
Thyroxin-binding Globulin 
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Thyroxin-binding Prealbumin 
Albumin 
Thyroid Hormone: 
Free and Protein Bound Form 
Free T3 and T4 is the physiologically active form. Free T3 and T4 coordinates the 
feedback mechanism of hormone action. 99.98% of the T4 in plasma is bound; the 
free T4 level is only about 2 ng/dL. T3 is not bound to quite as great an extent; 
0.2% (0.3 ng/dL) is free. The remaining 99.8% is protein-bound 
 
Thyroid Hormone-Mode of Action: 
Thyroid Hormones Belong to the lipophilic family of Hormones. Upon reaching 
the target tissue, freely permeate the plasma membrane. They have intranuclear 
receptors, Thyroid Hormone Response Elements on The DNA. Upon binding 
Thyroid Hormone alter gene expression and increase cellular metabolism. 
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3.4.3 REGULATION OF THYROID HORMONA SYNTHESIS: 
Thyroid function is regulated primarily by variations in the circulating level of 
pituitary TSH. TSH secretion is increased by the hypothalamic hormone 
thyrotropin-releasing hormone and inhibited in a negative feedback fashion by 
circulating free T4 and T3. The effect of T4 is enhanced by production of T3 in the 
cytoplasm of the pituitary cells by the 5'-D2 they contain. TSH secretion is also 
inhibited by stress, and in experimental animals it is increased by cold and 
decreased by warmth. 
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3.4.4 BIOLOGICAL ACTIONS OF THYROID: 
Hormones: 
T3 and T4 (Almost all is deiodinated by one iodide ion, forming T3) bind with 
nuclear receptor, activate and initiate genetic transcription. ---- mRNA. Protein 
synthesis in cytoplasmic ribosomes ---- general increase in functional activity 
throughout the body. 
On Metabolism: 
Calorigenic action of thyroid hormones: 
Increase O2 consumption of most tissues in the body, increasing heat production 
and BMR. 
Mechanism of calorigenic effect of thyroid hormones may be: Enhances Na+-K+ 
ATPase activity. Causes cell membrane of most cells to become leaky to Na+ ions, 
which farther activates sodium pump and increases heat production. 
Effect on metabolism of protein, carbohydrate and fat: 
On Protein Metabolism: 
Normally, T4 and T3 stimulates proteins synthesis and enzymes, increasing 
anabolism of protein and causing positive balance of nitrogen. In hyperthyroidism, 
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catabolism of protein increases, especially muscular protein, which leads weight-
loss and muscle weakness.  
On carbohydrate metabolism: 
Increase absorption of glucose from the gastrointestinal tract. Enhance 
glycogenolysis, and even enhanced diabetogenic effect of glucagon, cortisol and 
growth hormone. Enhancement of glucose utilization of peripheral tissues. 
3) Effect of Thyroid Hormones On fat metabolism: 
Accelerate the oxidation of free fatty acids by cells. Increase the effect of 
catecholamine on decomposition of fat. Promote synthesis of cholesterol. Also 
increase decomposition of cholesterol by liver cells. Net effect of T3 and T4 is to 
decrease plasma cholesterol concentration because the rate of synthesis is less than 
that of decomposition. 
2. Effect of thyroid hormones on growth and development: 
Essential for normal growth and development especially skeletal growth and 
development. Stimulate formation of dendrites, axons, myelin and neuroglia. A 
child without a thyroid gland will suffer from cretinism, which is characterized by 
growth and mental retardation. Without specific thyroid therapy within three 
months after birth, the child with cretinism will remain mentally deficient 
throughout life. 
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3. Effects of thyroid hormone on nervous system: 
Thyroid hormones increase excitability of central nervous system. In 
hyperthyroidism, the patient is likely to have extreme nervousness, many 
psychoneurotic tendencies including anxiety complexes, extreme worry and 
paranoia, and muscle tremor. Thyroid hormones can also stimulate the sympathetic 
nervous system. The hypothyroid individual is to have fatigue, extreme 
somnolence, poor memory and slow mentation.  
4. Other effects of thyroid hormone: 
(1) Effect on Cardiovascular system: 
Significant effect on cardiac output because of increase in heart rate and stroke 
volume, (may through enhance calcium release from sarcoplasmic reticulum). 
(2) Effect on Gastrointestinal Tract: 
Increase the appetite and food intake by metabolic rate increased. Increase both the 
rate of secretion of the digestive juices and the motility of the gastrointestinal tract. 
Lack of thyroid hormone can cause constipation. 
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3.5 GALLSTONES:  
Inspite of extensive research in the field of gallstones nothing conclusively has 
been put forward regarding the etiology and exact sequences of events that leads to 
the formation of gallstones. 
The major question is why gallbladder forms stones in few people alone. The 
subject of interest has turned towards what makes gallbladder a factory for 
gallstone production. 
Most of the studies conducted were from the western world where cholesterol 
stones are common. Studies in India are limited and mixed stones are more 
prevalent in India. 
3.5.1 Gallbladder stones: 
 Clinical classification of Gallbladder stones: 
1. Pure cholesterol stone  : 10% 
2. Pigment stone            : 15% 
3. Cholesterol pigment mixed stone : 75-80% 
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These can be analyzed by color chromatography, thin layer chromatography and 
X-ray diffraction. In 1924, Aschoff classified the stones into 4 categories: 
1. Inflammatory. 
2. Metabolic : Pure pigment (calcium Bilirubinate) and pure cholesterol 
3. Combination stones :  
            Primary – metabolic 
           Secondary - Inflammatory 
4. Stasis stones : 
Cholesterol Stones: 
Cholesterol is usually present as single crystal mainly as cholesterol monohydrate. 
Cholesterol stones may also contain carbonate and calcium palmitate. They are 
usually single, light yellow or even pure white, rounded or oval, being compared to 
unripe mulberries. 
Pure Pigment Stones (Calcium Bilirubinate): 
They are multiple, small and dark. Two types are recognized:  
1. Calcium Bilirubinate stones found in oriental countries are associated 
with Ascariasis or E.coli. 
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2. Pure pigment stones occurring without any infection but sometimes with 
hemolysis. 
These stones are dark or reddish brown and fragile. Some stones are black or dark 
green 
Mixed Stones: 
These form the majority of the stones (75-80%) which are multiple and 
multifaceted. The central portion of the stones represents the events occurring 
during initial stages of stone formation. They contain cholesterol, pigments, protein 
and sometimes parasites. 
3.5.2 CBD Stones:  
Classification of common bile duct stones: 
Biliary stones in general, may be classified as predominantly cholesterol or 
predominantly pigment in composition. 
Cholesterol stones – 95% 
Pigment stones  – 5% 
Primary common bile duct stones: 
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The stones that are formed primary in the common bile duct are called primary 
stones and those originating in the gallbladder are secondary stones. Almost all 
primary stones are of pigment stones. 
There are two types of pigment stones – black and brown. Both types have calcium 
bilirubinate as their principal compound. Brown pigment stones occur primarily in 
the common bile duct and are closely associated with bacteria. Black pigment 
stones are found chiefly in gallbladder. 
Secondary (retained) common bile duct stones: 
Secondary common bile duct stones are those that have migrated into the biliary 
system from the gallbladder. Approximately 11% of patients with gallbladder 
stones will have associated common duct stones at the time of operation 
Retained common bile duct stones are those that present after cholecystectomy, 
with or without concomitant bile duct exploration, and are secondary rather than 
primary stones. 
3.5.3 NATURAL HISTORY 
Gallstones: Majority of patients with gallstone disease are asymptomatic and 
remain same throughout life. 
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For unknown reasons some patient’s progress to a symptomatic stage with biliary 
colic by a stone obstructing cystic duct. 
Symptomatic gallstones may progress to complication related to gallstones like. 
Acute cholecystitis/chronic cholecystitis 
Mucocoele 
Empyema 
Gallstone pancreatitis 
Choledocholithiasis with or without cholangitis 
Cholecystocholedochal fistula 
Cholecystoduodenal fistula 
Cholecystoenteric fistula 
Gallstone ileus/Gallbladder malignancy 
Rarely complications of gallstones is presenting features 
Asymptomatic gallstones are diagnosed incidentally on USG/CT scan/laparotomy 
1-3% of asymptomatic individuals becomes symptomatic per year (table1) 
complicated gallstone disease develops on 3-5% of symptomatic patients per year. 
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Over a 20 years period about 2/3rd of asymptomatic patients with gall stones 
remain symptom free. 
CBD calculi: 
The natural history of choledocholithiasis is unpredictable. Small stones may pass 
spontaneously into the duodenum without causing symptoms or they may 
temporarily obstruct the pancreatic duct, induce an episode of pancreatitis and then 
pass into the duodenum with relief or symptoms, stones that do not pass 
spontaneously may reside in the bile duct for long symptom free period and then 
suddenly precipitate and episode of jaundice or cholangitis. 
Choledocholithiasis may appear in the following five ways: 
i) Without symptoms 
ii) Biliary colic 
iii) Jaundice 
iv) Cholangitis (intermittent pain, fever, jaundice – CHARCOT TRIAD) 
v) Pancreatitis  
The last four of these may appear in all possible combination. 
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3.6 INCIDENCE:  
 
It has been a matter of discussion for decades whether the thyroid disorders are 
responsible for the gall stone disease. Several studies have shown the possible 
relationship between hypothyroidism and gall stone disease. These studies include 
the link between thyroid failure and disturbances of lipid metabolism that may 
consecutively lead to a change of the composition of the bile. 
A study was conducted by P. Sundeshwari et al in 2014 at GRH Madurai on 200 
gallstone patients. Among them, 18 patients had subclinical hypothyroidism and 6 
patients had clinical hypothyroidism. A total of 12% of gallstone patients were 
diagnosed to have hypothyroidism. This shows that there is association of 
hypothyroidism with gallstone disease [12]. 
In a study conducted in August 2016 Aishwin Saravanakumar in Coimbatore 
(Tamil Nadu), out of 50 patients 34% were male and66% were female. In the study 
66% were euthyroid, 14% were subclinical hypothyroid, 10% hypothyroid and 
10% hyperthyroid. Of the 14% subclinical hypothyroid, 4% were in the age group 
30-45, 10% were in the age group of more than 45. Hypothyroidism was more in 
female patients (80%) [13]. 
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In a study conducted by Mir Mujtaba Ahmad in 2015 at SMHS Srinagar over a 
period of 2 years on a total of 100 patients, 50 diagnosed as having cholelithiasis 
and 50 having choledocholithiasis. A complete history, detailed clinical 
examination followed by evaluation as per protocol was done. There was an 
increased prevalence of choledocholithiasis with increasing age (maximum 
patients in age group 51- 60) with female predominance in patients diagnosed as 
choledocholithiasis, thereby implying increasing age and female gender as risk 
factors for choledocholithiasis. There was a prevalence of hypothyroidism in 8% of 
cholelithiasis group with subclinical hypothyroidism present in maximum number 
of patients (75%) and clinical in 25% of patients. Abnormal high levels of serum 
TSH and cholesterol were reported in 12 cases (8%) and in 15 cases (10%) 
respectively [14]. 
A cross sectional study was done in Al-Sader Teaching Hospital in Al-Najaf 
citybetween15th ofFebruary2008 and1st of November 2009 of 225 cases were taken 
to show relation between gallstone and hypothyroidism. Out of 225 patients with 
gallstone 198 (88%) were females and 27 (12%) males. Thyroid disorder inform of 
hypothyroidism was found in 24 (10.6%), from this percentage 22 (9.7%) were 
females and from this 18 (8.0%) were subclinical and 4 (1.7%) were clinical 
hypothyroidism and males were 2 (0.9%) with subclinical cases. Out of 225 cases 
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with gallstones, 22 (9.7%) cases complaining from goiter with peak age between 
51- 60 years [15]. 
A study conducted by Suaad L Ibrahim in 2014 to measure level of TSH in serum 
blood of (100) patients with gallstones diagnosed by sonographically or current 
cholecystectomy with regarded to the diﬀerences between sex of patients and 
predominated of gallstone type with age. In this study, there were 10 (0.1%), 
38(38%), and 52(52%) patients for low, normal and high levels of TSH 
respectively. It showed a high proportion of females (53%) compared to the males 
(47%). Females were demonstrated  high prevalence of normal TSH (71.69%) , 
13.20% and 15 for both high and low levels TSH respectively. while males 
demonstrated high prevalence (95.47%) of high levels of TSH and (4.53%) of low 
levels of TSH [16]. 
 
A study conducted by Rana Ranjit Singh in 2016 demonstrated the percentage of  
males with gallstone disease diagnosed as hypothyroid, euthyroid and hyperthyroid 
is 24%, 64% and12%respectively. The percentage of females with gallstones 
diagnosed hypothyroid, euthyroid and hyperthyroid was 24.4%, 65.85 and 1% [17] 
respectively.  
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In a study done by Johanna L, Gediminas K (2007), the prevalence of subclinical 
hypothyroidism was 11.4% in gallstones and none of the patients was clinically h  
ypothyroid [18]. The results of thyroid profile in our study were comparable to 
other studies. In our study the number of cases with low FT4 were 27 against none 
in controls. All controls had normal FT4 levels. P value of the observation is 
.014103 which is significant (p<. 05).  This suggested that low FT4 is involved in 
the pathogenesis of gallstones. In our study, the number of case with low FT3 were 
25 against no controls. All controls had normal FT3 hormone level. P value is 
0.0194 which is significant. This indicated that low thyroid hormone level is 
involved in the pathogenesis of gallstone disease [18]. 
In a study Hassan H Zaini et al in 2008 on 225 patients, 24 were of hypothyroid. 
Out 0f these in laboratory investigation we found that20 cases recorded with high 
TSH and low T3, T4 , 3 cases with high TSH and low T4 and 1 case with high 
TSH and low T3. These results are comparable to our study where out of 200 cases 
27 have low FT4 and 25 have low FT3 [15]. 
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3.7 PATHOGENSIS:   
3.7.1 Hypothyroidism leading to gall stone formation: 
In general, the pathogenesis of gallbladder stone is a complex process involving 
mechanisms aﬀecting bile content formation and bile ﬂow. There are many factors 
that may lead to the formation of gall stones in hypothyroid patients. Based on the 
investigations currently available, it cannot be concluded whether hypothyroid 
individuals develop isolated gallbladder stones or present with both gallbladder 
stones and CBD stones. However, based on what is known about the effect of 
hypothyroidism in formation of gallstone and CBD stones, hypothyroidism has risk 
for both gallbladder stone and CBD stones. In hypothyroidism, the lack of 
thyroxine may lead to following abnormality. (1) Liver cholesterol metabolism 
abnormality [19] resulting in bile cholesterol super saturation, which in turn 
impairs the motility [20], contractility [21], and ﬁlling [22] of the gallbladder. 
Above effects, contributes to the retention of cholesterol crystals and to the 
nucleation and growth of gallstones [20]; (2) Bile secretion from hepatocytes are 
reduced [23] resulting in impaired clearance of precipitates from the bile ducts; (3) 
delayed bile ﬂow due to reduced SO relaxation [24, 25] and thus the formation and 
accumulation of gallstones. 
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THs regulate multiple functions in virtually most type of vertebrate tissue [26, 27]. 
Most actions of THs can be explained by their interaction with nuclear receptors. 
THs actions are expressed in a tissue- and development stage-speciﬁc fashion [28–
32]. In human, the SO expresses both TR βand β [33].Any acute-type response of a 
cell to THs is unlikely to involve a transcriptional mechanism. Instead it’s a result 
of nongenomic mechanisms involving extra nuclear sites of action [34–44]. In 
general, thyroid hormone actions are more of intracellular events that require 
transport across the plasma membrane. Recently, several active and speciﬁc 
thyroid hormone transporters have been identiﬁed. Transporters consist of 
monocarboxylate transporter 8 (MCT8), MCT10, and organic anion transporting 
polypeptide 1C1 (OATP1C1) [45, 46]. 
3.7.2 Liver cholesterol metabolism affected by hypothyroidism: 
Thyroid hormones have variable effects on cholesterol metabolism, because 
thyroid function regulates cholesterol synthesis and degradation and mediates the 
activity of key enzymes. The cholesterol lowering effect of thyroid hormones 
mediates through an increased expression of LDL receptors at the hepatic and 
peripheral levels. The number of LDL receptors in human murine fibroblasts and 
hepatocytes was regulated by T3. The hyperthyroid state is associated with 
increased fat utilization. Due to increased synthesis in the liver and from 
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triglyceride lipolysis in white adipose tissue. Thyroid hormone promotes lipolysis 
indirectly. By increasing the catecholamine-induced stimulation of the hormone-
sensitive lipase in adipose tissue. 
 
De novo lipogenesis is reduced in hypothyroidism, mainly in the liver. This is 
corrected by thyroid hormone. Furthermore, hypothyroidism is associated with 
reduced lipoprotein lipase (LPL) and hepatic lipase activities. Both will respond to 
thyroid hormone replacement. In the transition to thyrotoxicosis, these effects 
continue to increase, in a T3 concentration-dependent manner [47, 48].  
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Fletcher and Myant reported a decrease in in vivo cholesterogenesis from 
hypothyroid animal. By thyroxine replacement caused a stimulation of cholesterol 
synthesis in these animal. Boyd has noted similar responses of cholesterol 
synthesis to hypothyroid and hyperthyroid states. 
Total serum cholesterol is reduced in thyrotoxicosis and increased in 
hypothyroidism. In a dose-dependent manner thyroid hormones reduce cholesterol 
serum concentration. This is result of thyroid hormonal stimulation of hepatic 
cholesterol uptake by LDL receptors. Thyroid hormones increase the concentration 
of the LDL receptor by stimulation of the expression of sterol regulatory element 
binding protein-2 (SREBP-2). SREBP is a transcription factor that enhances LDL 
gene transcription and expression. Thyroid hormones also increase cholesterol 
synthesis. This achieved by stimulating the rate-limiting enzyme 3-OH-methyl 
glutaryl CoA reductase (HMG CoA reductase). 
Serum hypercholesterolemia in low thyroid hormone level may cause bile to 
supersaturate in cholesterol. A direct effect of cholesterol supersaturated bile in 
reduced motility, depressed contractility, and impaired filling of the gallbladder. 
These will lead to retention of bile in the gallbladder. This may contribute to the 
retention of cholesterol crystals. These causes sufficient time for nucleation and 
continuous growth into mature gallstones. 
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3.7.3 Reduction in hepatic bile secretion due to hypothyroidism: 
In a prospective study in humans, the dynamic Tc-99m HIDA scintigraphy 
performed in the acute hypothyroid stage after thyroidectomy. The results showed 
that the hepatic maximal uptake and appearance of radioactivity in the large bile 
ducts at the hepatic hilum was similar to the euthyreotic stage in the same patients.  
In humans, hepatocytic bile secretion may not be significantly reduced in the early 
phase of hypothyroidism. Where as in rats, bile secretion rate can be measured by 
cannulating bile ducts proximal to the SO (to block out the SO effect). In 
prolonged hypothyroidism decreased bile secretion is noted. Thus in prolonged 
hypothyroidism, decreased bile hepatic secretion may have at least some impact on 
the delayed bile flow. 
3.7.4 Effect of bile flow in duodenum in hypothyroidism: 
In a prospective human study [49], hepatic clearance was significantly decreased. 
The hilum-duodenum transit time had a tendency to increase in the hypothyroid 
stage after thyroidectomy. But when compared to the euthyreotic stage in the same 
patients transit time is different. As the hepatic maximal uptake and the appearance 
of radioactivity in the large bile ducts at the hepatic hilum were similar in the 
hypothyroid and euthyreotic stages of this study. The findings are hardly 
attributable to different hepatic secretion but when compare to biliary system, it 
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strongly suggest that bile flow into the duodenum is reduced in the hypothyroid 
stage [49]. The above mentioned effects could be due to changes in bile 
composition and gallbladder motility, and because of changes in the resistance to 
flow, that is, in the SO motility. 
3.7.5 Hypothyroidism leads to impaired relaxation of sphincter of 
oddi: 
The existence of gastrointestinal activity in relation with thyroid hormone like 
hypo activity has been well known for decades [50–56]. For example, anal canal 
pressure and in lower esophageal sphincter pressure are related with the eﬀect of 
thyroxine [57, 58].The eﬀect of THs on smooth muscle contraction depends on the 
smooth muscle type and the species under study. Thyroid hormone have a direct, 
relaxing effect on vascular smooth muscle contractility [40]. This effect is 
mediated by intra nuclear binding of TH to the TR [59, 60, 61]. Other by 
nongenomic mechanisms involving extra nuclear sites of action [43]. The 
potassium (K+) channel blocker like glibenclamide attenuates triiodothyronine-
induced vasodilatation in rat skeletal muscle arteries. T3 (triiodothyronine)-
induced vasodilatation may thus be mediated by ATP-sensitive K channels [62]. 
Sandblom et al. [63] ﬁrst demonstrated the hormonal action of cholecystokinin 
(CCK) on the SO in 1935. Since then several other hormones have been shown to 
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affect SO activity [64–68]. In 2001 [69], in pig experiments it was shown for the 
ﬁrst time that thyroxine has a direct effect on SO contractility in physiological 
concentrations. Triiodothyronine had a similar effect on thyroxine. Cortisone, 
estrogen and testosterone had no effect. Thus the effect of THs is not an unspeciﬁc 
effect of any hormone. Thyroxine reduced receptor-mediated acetylcholine and 
histamine-induced SO contraction. Thyroxine effect doesn’t depends on unspeciﬁc, 
KCl-induced SO contraction, but instead shows a direct effect of thyroxine on the 
control mechanisms of SO motility. As the effect of thyroxine on the pre 
contracted SO is relaxing. The absence/insufficient concentration of thyroxine may 
result in increased tension of the SO in hypothyroidism [33]. A similar relaxant 
effect of thyroxine was also shown in human SO specimens. Thus shows that the 
ﬁnding may also be of clinical signiﬁcance [33]. 
3.7.6 Mechanisms by which thyroxine mediates SO relaxation: 
Several examinations were conducted to determine how the relaxant effect of 
thyroxine on SO is mediated [33]. The experiments with a-and ß-adrenoceptor 
antagonists, NO synthesis inhibitor, and the elimination of nerve function with 
tetrodotox in showed that the thyroxine-induced relaxation of SO is not mediated 
via neural effects. Human SO was shown to express TR ß1and ß2. The presence of 
TRs [33] in the SO is necessary for relaxation effect. There is no sufficient 
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evidence that thyroxine exerts its pro relaxant effect via a hormone-receptor 
complex action. However, the experiments with different incubation times of 
thyroxine showed that the underlying cellular mechanisms involved do not act 
immediately but require a certain time lag. The theory regarding that at least part of 
the action of thyroxine is TH-TR mediated [33].The passage of TH through cell 
membrane, cytoplasm, and nuclear membrane and binding to a nuclear protein 
(TR) is a relatively fast event. But transcriptional and translational regulation is 
time-consuming, and probably explains why the relaxant effect is not immediate. 
Thus, the effect of thyroxine could be mediated by regulatory proteins which are 
synthesized as a result of thyroxine induced gene expression.                
 
K+ channels can be modulated by neurotransmitters and other messengers in 
smooth muscle cells. These effects are often functionally important in the whole 
tissue [70]. Similarly to what has been shown in rat skeletal muscle arteries, where 
triiodothyronine-induced vasodilatation is mediated by ATP-sensitive K+ channels 
[62]. It was shown in SO that the eﬀect of thyroxine on SO smooth muscle is 
mediated via the opening of ATP-sensitive K+ channels [33]. This results in 
hyperpolarization, which closes all membrane Ca channels. This reduces Ca 
2+inﬂux, allowing only limited contraction of the smooth muscle [71]. 
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The pro relaxant effect of thyroxine is mediated via transporter protein and via 
binding to nuclear receptors. Combined actions may lead to the activation of K+ 
channels [33]. The opening of K+ channels is followed by hyperpolarization. 
These effect will closes cell membraneCa2+channels, reduces Ca2+inﬂux, and 
results in reduced contraction of the SO smooth-muscle cell in response to any 
speciﬁc stimulus. 
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4 MATERIALS AND METHODS 
This is a prospective study conducted in the department of General surgery, 
GOVERNMENT STANLEY MEDICAL COLLEGE FORM (OCT-2016 TO AUG 
2017) 
4.1 SOURCE OF DATA: 
The patients admitted in our hospital wards for management of gall bladder 
stone from October 2016 TO August 2017 will be taken up for the study.   
4.2 METHOD OF COLLECTION OF DATA (including sampling 
procedure, if any):   
• Details of cases, full history, clinical examination and symptoms and signs 
of hypothyroidism (loss of appetite, gaining weight, tiredness, constipation, 
cold intolerance, menstrual disturbances, bradycardia, presence or absence 
of goiter etc.) 
• Routine Blood Investigation. 
• USG Abdomen 
• Thyroid function test(T3,T4,TSH) 
• USG Neck 
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• Lipid profile          
4.3 INCLUSION CRITERIA FOR THE STUDY:    
Patients with cholelithiasis (the presence of gallstones on ultrasound) 
4.4 EXCLUSION CRITERIA:                                                                     
        Excluded were patients with a history of previously diagnosed or treated 
thyroid function abnormalities, history of thyroidectomy, pregnancy, serious 
underlying diseases, sepsis or cholangitis and those prescribed medications known 
to affect the thyroid function test such as phenytoin, carbamazepin, 
metoclopramide, amiodarone, and lithium and statins. 
4.5 SAMPLE SIZE 
All patients admitted in ward for a period of 11 months according to inclusion 
criteria. 
4.6 TYPE OF STUDY: Prospective time bound study. 
4.7 DESIGN OF THE STUDY 
 Patients are divided according to history, clinical examination, and USG neck and 
lab estimation of T3, T4, and TSH. 
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1. Subclinical hypothyroidism: symptom free patient with TSH concentration 
above upper limit of normal range and T3/T4or both decrease below normal 
limit. 
2. Clinical hypothyroidism: in which there are symptoms of hypothyroidism 
with TSH level above the upper limit and T3/T4or both decrease below 
normal limit. 
3. Euthyroid group: where clinical and lab tests are within normal range. 
(All these groups may present with or without goiter).  
 
 
 
 
 
 
 
 
70 
 
5 OBSERVATION AND RESULTS 
This was a prospective study done in department of general surgery Stanley 
medical college Chennai from October 2016 to August 2017. 
This study included 60 gallstone patients who were studied prospectively over a 
period of 11 months from October 2016 to August 2017. 
5.1 Demographic profile: 
We included 60 patients diagnosed with Gallstone disease; 61.67% were females 
and 38.33% were males [table 1]. In this study, female are more compare to male, 
may be due to earlier symptomatology of gallstone disease as well as higher 
incidence of thyroid disease in women. 
Table 1 
Sex  No. of Patients Percentage 
Male  23 38.33% 
Female  37 61.67% 
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The predominant age group was 51-60 years constituting 36.67% of patients [table 
2]. Youngest patient age was 21 years and oldest was 80 years of age. 
 
Table 2 
Age  No. of patients Percentage 
21-30 8 13.33% 
31-40 12 20% 
41-50 14 23.33% 
51-60 22 36.67% 
>60 4 6.67% 
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Male Female
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5.2 Thyroid Status: 
Of the 60 patients, majority of patients are euthyroid status 52(86.67%) [Table 3]. 
6 (10%) patients are subclinical hypothyroidism, 2 (3.33%) were clinical 
hypothyroidism. 
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Table 3  
 No. of 
Patients 
Percentage  
Subclinical Hypothyroidism 6 10% 
Euthyroid Status 52 86.67% 
Clinical Hypothyroidism 2 3.33% 
 
 
 
Of the 52 patients with euthyroid status, 21 of them belongs to age group of 51-60 
years [table 4]. Subclinical hypothyroidism patients were almost distributed 
equally among age group mentioned.   
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Table 4: 
 Total  Male  Female  Subclinical 
hypothyroidism 
Euthyroid  Clinical 
hypothyroidism 
21-30 8 2 6 2 6 0 
31-40 12 3 9 1 10 1 
41-50 14 6 8 2 12 0 
51-60 22 10 12 1 21 0 
>60 4 2 2 0 3 1 
 
 
 
 
 
Of the 60 patients, 52 were diagnosed with gallstone only and 8 were diagnosed 
with gallstone and CBD stones [table 5]. 
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Table 5 
 Euthyroid  Subclinical 
Hypothyroidism 
Clinical 
hypothyroidism 
Gallstones  45 5 2 
Gallstones with 
CBD stone 
7 1 0 
 
 
 
5.3 Lipid Profile: 
In this study from table 6, total cholesterol levels are increased in 18 patients and 
increased total triglycerides seen in 13 patients.   
Table 6 
 TC >250 mg/dL TGL >150 mg/dL 
Gallstones  15 12 
Gallstones with CBD 
stones 
3 1 
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In this study, hyperlipidemia seen in 7 of the hypothyroidism patients [table 7]. 
Table 7 
 TC >200 mg/dL TGL >150 mg/dL 
Euthyroid  11 9 
Subclinical 
hypothyroidism 
5 4 
Clinical hypothyroidism 2 0 
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6 DISCUSSION 
Earlier, an association between gallstone and diagnosed hypothyroidism and 
delayed emptying of the biliary tract is shown. This relation was showed with a 
help of experimental and clinical hypothyroidism, explained at least partly by the 
lack of pro relaxing effect of T4 on the sphincter of oddi contractility. In recent 
years, experiments have demonstrated that low bile flow and sphincter of Oddi 
dysfunction are important functional mechanisms that may promote biliary stone 
formation. 
In this study, 61.67% were female compare with 38.33% of males. This is because 
of early symptomatology of gallstones in females and higher incidence of thyroid 
disease in women. In a study conducted by Nazim Hayat et al in 2012 at 
Faisalabad, out of 200 patients that were included in the study, 166(83%) were 
females and 34(17%) were male. These results are very similar to our study. It has 
been documented in many studies that being female is the single most important, 
non-modifiable cause of gallstones. 
In this study, the population with gallstones was more in the age group of 51-60 
compare to other age groups. It is expected that risk factors of gallstones or thyroid 
dysfunction increases with increase in age. In a prospective study conducted by 
Chen CY et al in July 1998 in 3647 Chinese patients, factors manifesting an 
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increase in risk for the development of gallstone disease were age (p<.05) [73]. In 
a study by Henry Volzke et al in 2005 to evaluate the independent risk factors for 
gallstone formations in a region with high cholelithiasis prevalence. The study was 
conducted with data available of 4202 patients and found advancing age, increased 
BMI and low HDL levels as independent risk factors for the development [74] of 
cholelithiasis. Similar study done by Mirella Fraquelli et al in October 2001 
analyzed 330 patients. They observed that gallstones were significantly associated 
with age (p<0.001) being 13%, 36% and 51% in patients aged 44 years and 
younger, 45 to 59 years and 60 years and older, respectively [75]. 
In this study, we have evaluated the association of thyroid dysfunction in patients 
with gallstones. In a study done by JOHANNA L, GEDIMINAS K (2007), the 
incidence of subclinical hypothyroidism was 11.4%, which is close to that of this 
study (10%). The prevalence of hypothyroidism was nil in that study, but in this 
study prevalence of hypothyroidism is 3.33%. In this study, subclinical 
hypothyroidism seen in 5 of the patients with gallstones alone compare with one 
patient having gallstones and CBD stones.  
Serum TSH is a hallmark of thyroid dysfunction. The subclinical hypothyroidism 
is characterized by increased levels of serum TSH with normal T4 levels and lack 
of symptoms. A study by Laukkarinen has shown hypothyroidism to be a common 
problem among patients with gallstone diseases. He concluded that 
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hypothyroidism played a role in the formation of gallstones secondary to its effects 
of SO relaxation. These effects in turn might influence on emptying of the biliary 
system. 
Patients with hypothyroidism are more prone to have abnormality in lipid profile. 
In this study, 5 of the patients with subclinical hypothyroidism are having elevated 
levels of total cholesterol and total triglyceride. The mechanism leading to this is 
multifactorial. Thyroid hormones influence the synthesis, absorption and usage of 
cholesterol in human body. So, it can be concluded that serum TSH level is an 
independent factor that could be considered a risk factor for the formation of 
gallstones.  
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7 CONCLUSION 
This study concludes that 
1. There is a relationship between thyroid dysfunction particularly 
hypothyroidism and gallstone diseases. 
2. Hypothyroidism is seen more in GB stones patients compare with CBD 
stone patients. 
3. Subclinical hypothyroidism is more common than clinical hypothyroidism. 
4. Hypothyroidism has higher prevalence in females than males. 
5. High cholesterol levels are seen in gallstone disease with thyroid 
dysfunction. 
6. Lipid profile abnormality is seen more in GB stones compared with CBD 
stones.  
So we recommend that surgeon should be aware of thyroid background in patients 
with biliary stone disease, TSH should be measured as most are sub clinically 
hypothyroid along with lipid profile. 
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                                       MASTER CHART
Name Age/sex ID T3 T4 TSH TC TGL VLDL USG HYPOTHYROID FEATURES HYPERTHYROID FEATURES GOITER WITH/WITHOUT
ARJUNAN 52/M 1677253 2.58 pg/ml 1.28 ng/dl 1.12 171 132 26 CHOLILETHIASIS NO NO WITHOUT
THANGAPPAN 65/M 1704507 3.26 1.18 1.37 213 162 CHOLILETHIASIS NO NO WITHOUT
NOORNISHA 21/F 1701142 3.12 1.14 8.54 256 146 21 CHOLILETHIASIS NO NO WITHOUT
BALAMMAL 60/F 1703134 1.32 2.22 2.96 187 119 CHOLILETHIASIS NO NO WITHOUT
MOHAN 61/M 1705144 2.73 1.58 2.97 228 108 CHOLILETHIASIS NO NO WITHOUT
MUBARAK 44/M 1705099 2.78 1.73 1.02 180 57 CHOLILETHIASIS NO NO WITHOUT
SHANMUGAM 57/M 1706414 1.94 1.13 0.652 198 78 CHOLILETHIASIS NO NO WITHOUT
RANI 61/F 1705190 3.13 1.29 13.13 278 157 CHOLILETHIASIS YES NO WITHOUT
BABY THOMAS 55/F 1709531 122(60-200) 8(4.5-12) 3.20(0.3-5.5) 186 167 CHOLILETHIASIS NO NO WITHOUT
SUGUNA 46/F 1710527 2.8 1.33 6.84 206 140 CHOLILETHIASIS NO NO WITHOUT
RAJAMMAL 45/F 1713228 2.6 1.39 1.55 209 177 CHOLILETHIASIS NO NO WITHOUT
MEENA 40/F 1716460 3.97 1.63 0.925 129 56 CHOLILETHIASIS NO NO WITHOUT
LAKSHMI 52/F 1715039 2.6 1.2 1.1 188 118 CHOLILETHIASIS NO NO WITHOUT
PALANI 46/M 1729348 2.44 1.3 1.08 98 102 CHOLILETHIASIS NO NO WITHOUT
VENKATAPPAN 60/M 1726377 1.57 1.16 1.7 108 67 ACUTE CALCULUS CHOLECYSTITIS NO NO WITHOUT
VASANTHA 50/F 1726321 2.42 1.44 1.24 167 149 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
SHARMILA 29/F 1726338 2.5 1.27 3.34 146 121 CHOLILETHIASIS NO NO WITHOUT
DHANALAKSHMI 42/F 1725135 2.2 1.1 2.56 183 147 CHOLILETHIASIS NO NO WITHOUT
ANUSIYA 28/F 1716178 2.32 1.54 2.46 151 120 CHOLILETHIASIS NO NO WITHOUT
SHARADHA 80/F 1732155 1.56 1.1 1.9 143 225 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
LATHA 39/F 1733026 2.46 1.2 0.968 138 116 CHOLILETHIASIS NO NO WITHOUT
RAMALINGAM 55/M 1734743 3.4 1.27 3.36 152 110 CHOLILETHIASIS NO NO WITHOUT
JAMEENA 31/F 1735312 2.5 1.2 2.16 166 80 CHOLILETHIASIS NO NO WITHOUT
KANNAN 38/M 1737192 2.9 1.23 1.73 146 89 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
KANNAN 41/M 1738127 2.4 1.67 2.3 194 144 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
SUMATHI 40/F 1734561 2.68 1.23 15.4 265 136 CHOLILETHIASIS YES NO WITHOUT
SALIMA 50/F 1737606 3.47 1.24 2.55 208 93 CHOLILETHIASIS NO NO WITHOUT
CHANDRA 60/F 1734759 2.6 1.2 2.1 210 110 CHOLILETHIASIS NO NO WITHOUT
JOTHI 57/F 1741635 2.6 1.6 1.2 123 210 CHOLILETHIASIS NO NO WITHOUT
KOTHANAYAGI 60/F 1742797 2.08 1.08 1.71 183 110 CHOLILETHIASIS NO NO WITHOUT
KASTHURIAMMAL 58/F 1744326 2.03 1.2 2.2 194 116 ACUTE CALCULUS CHOLECYSTITIS NO NO WITHOUT
THULAKKANAM 55/F 1747523 2.3 1.6 3.4 245 112 CHOILETHIASIS NO NO WITHOUT
VICTORIA 29/F 1744250 2.5 1.1 2.9 154 98 CHOLILETHIASIS NO NO WITHOUT
RANI 55/F 1745984 2.34 1.34 3.6 176 103 CHOLILETHIASIS NO NO WITHOUT
VIMALA 45/F 1742455 2.09 1.76 2.65 198 125 CHOLILETHIASIS NO NO WITHOUT
RABIYA 45/F 1705628 2.45 1.1 7.6 210 167 CHOLILETHIASIS NO NO WITHOUT
PAVANAMMAL 60/F 1744314 2.56 1.05 2.96 198 115 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
ABITHA 33/F 1746195 2.02 1.6 3.2 168 114 CHOLILETHIASIS NO NO WITHOUT
SUBRAMANI 59/M 1743023 3.2 1.2 2.96 240 160 CHOLILETHIASIS NO NO WITHOUT
RAJENDRAN 52/M 1740893 2.6 1.06 3.25 199 110 CHOLILETHIASIS NO NO WITHOUT
ATHILALAKSHMI 30/F 1746873 2.05 1.5 3.06 187 154 CHOLILETHIASIS NO NO WITHOUT
SIVARAJ 23/M 1744965 2.54 1.09 2.56 165 136 CHOLILETHIASIS NO NO WITHOUT
RISHAKA PRIYA 33/F 1743031 2.69 1.26 3.41 193 140 CHOLILETHIASIS NO NO WITHOUT
ANANDHAN 50/M 1744661 3.01 1.87 3.98 241 118 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
MALA 38/F 1743313 2.41 1.56 2.63 230 120 ACUTE CALCULUS CHOLECYSTITIS NO NO WITHOUT
SUNDARAJAN 47/M 1733281 2.84 1.6 3.25 219 160 CHOLILETHIASIS NO NO WITHOUT
UMASHANKAR 37/M 1739278 2.9 1.8 3.78 200 145 CHOLILETHIASIS NO NO WITHOUT
UDHAYAKUMAR 31/M 1740664 1.96 1.01 6.5 213 154 CHOLILETHIASIS NO NO WITHOUT
NEELA 38/F 1733854 2.36 1.29 3.65 179 156 ACUTE CALCULUS CHOLECYSTITIS NO NO WITHOUT
RADHA 39/F 1735859 2.31 1.38 4.01 183 123 CHOLILETHIASIS NO NO WITHOUT
NARENDRAN 44/M 1733294 2.1 1.06 3.47 173 145 CHOLILETHIASIS NO NO WITHOUT
VENGAMMA 60/F 1734134 1.89 1.6 3.25 189 102 CHOLILETHIASIS NO NO WITHOUT
KUMAR 53/M 1732966 1.99 1.08 3.99 259 162 CHOLILETHIASIS NO NO WITHOUT
ANBU 28/M 1733783 2.9 1.65 3.78 198 127 ACUTE CALCULUS CHOLECYSTITIS NO NO WITHOUT
ANBU 51/M 1733473 3.12 1.23 3.56 210 136 CHOLILETHIASIS NO NO WITHOUT
KUMAR 53/M 1732966 1.96 1.59 5.9 249 152 CHOLILETHIASIS NO NO WITHOUT
SENTHAMIL SELVI 41/F 1732430 2.09 1.05 2.69 196 143 CHOLILETHIASIS NO NO WITHOUT
TAMILSELVI 30/F 1730897 2.01 1.06 6.3 256 149 CHOLILETHIASIS WITH CBD STONE NO NO WITHOUT
JAYABALAN 60/M 1733864 3.14 1.56 2.91 214 96 CHOLILETHIASIS NO NO WITHOUT
LUCY 54/F 1735678 2.95 1.96 3.5 240 111 CHOLILETHIASIS NO NO WITHOUT  
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Urkund Analysis Result 
 
Analysed Document:          thyroid and gallstones final.docx (D30909300) 
Submitted:                        9/30/2017 4:08:00 AM 
Submitted By:                     viveknagappa@gmail.com 
Significance:                     3 % 
 
Sources included in the report: 
 
THESIS.docx (D22568330) final thesis.doc (D30810446) 
https://consensus.nih.gov/2002/2002ERCPsos020Progra
m.pdf 
 
Instances where selected sources appear: 
 
14 
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PROFORMA 
 
 
Name :                                                   Age :               Sex :                            IPNO:  
 
Complaints presenting with Pain Abdomen                                     
               Acute 
               Chronic  
               Acute on chronic 
               Radiating to back 
               Relation to food  
 
Nausea :  
 
Vomiting :  
        Bilious  
        Non-Bilious  
 
Fever :                                                                              
 
Jaundice :  
 
H/o Trauma  
 
H/o Diarrhoea/Steatorrhoea  
 
PAST HISTORY  
    Similar episodes  
    Jaundice  
    Diabetes Mellitus / HT/PT 
 
 PERSONAL HISTORY  
     Alcoholic  
     Smoker  
    
GENERAL EXAMINATION  
    1) Fever  
    2) Pallor  
    3) Jaundice  
    4) Hydration  
    5) BP  
    6) Pulse Rate  
    7) Pedal Oedema 
 
 
 
Investigations 
 Urine :                BI  :  TC                        UREA 
     Alb                          DC                        CREATININE 
    Sugar                        ESR                      SUGAR 
    Deposit                     Hb%                        
  
Sr. Amylase :                                             Sr. Electrolyte  
FLP                                                                 Na+/K- 
LFT 
   Bilirubin  
  SGOT 
  SGPT                               
  ALK Phos.  
  Proteins  
 
X-ray chest PA view                       ECG 
          Abd.AP. view 
Post op follow up 
Examination of abdomen  
1)Any fullness  
2)Mass :    Location/Characteristics  
                  of mass/ number 
 
 
 3) Spleen, liver  
4) Free fluid  
USG Abdomen – gall stone - Number / Location / Size /  
                                                CBD stone    
                                       
 
 
 
Management : 
 
Open Cholecystectomy   
Laparoscopic Cholecystectomy 
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